growth led diabet segment sever new launch
maintain buy rate downgrad tp
deriv tp base forward price-to-earnings multipl
adjust ep provid upsid
potenti estim top-
line revenu grow
estim base follow factor strong
organ revenu growth strong growth across group
region newli launch product strong growth
oper perform adjust ep increas cash
medtron perform quarter strong due
growth revenu growth non-gaap ep
growth due growth market across
multipl busi geographi
free cash flow deliv
healthi margin expans continu increas
invest oper margin increas
quarter due sg expens
growth quarter led diabet grew
reflect strong demand minim hybrid
close loop system outsid
emerg technolog revenu doubl
quarter due launch guardian connect stand-alone
cgm sugar iq assist guardian connect
smart cgm use cognit comput capabl provid
person insight predict alert
compani name plc ordinari sharestickermdtstock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth plc januari
incom statement
non-
per share item
product perform develop
valuat consensu perform
growth revenu due strong growth
pain brain specialti therapi divis
septemb announc acquir mazor robot
plan close acquisit believ
integr mazor robot
stealthstat navig o-arm imag equip
well spine implant creat long-term
competit advantag spine market
minim invas therapi group grew led
balanc growth across si divis cvg
grew quarter high-singl digit growth
csh apv divis
sale growth estim
organ recent exchang rate hold remaind
mdt revenu would neg affect
current price-to-earnings averag price-to-earnings
due decreas stock price price-to-earnings show
huge fluctuat last three year due volatil
stock price price-to-earnings trail
downgrad tp expect
forward price-to-earnings multipl
perform per expect reduc
tp due stock market perform
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date sep inform medtron plc januari
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg restructur oper interest incom special interest non-oper minor incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli plc januari
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item medtron plc januari
flow oper activ increas compar
increas net cash provid led oper margin expans increas cash collect
custom well decreas cash paid supplier vendor certain litig payment cash
paid interest retir benefit plan contribut
provid invest activ decreas compar
decreas net cash provid attribut sale patient deep vein thrombosi
nutrit insuffici busi end octob result net
proce
use financ activ compar decreas
net cash use attribut repay senior unsecur term loan includ accru interest
repay ten-year cifsa senior note includ accru interest
end octob
depreciation- defer incom oper increas decreas decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end plc januari
plc deliv strong quarterli result growth revenu due
growth across segment region
net revenu increas compar
revenu increas organ basi due grow
market across multipl busi geographi
total revenu repres total revenu total
revenu non-u develop market repres total revenu
total revenu emerg market repres total
revenu
total revenu increas compar
total revenu non-u develop market
increas compar total
revenu emerg market increas
compar
compar
total revenu
 increas
compar
cog increas compar
cog revenu declin compar
cog revenu
declin
compar
decreas cog net sale favor affect infus
set recal diabet group along cost recogn relat
restor oper four puerto rico manufactur site
hurrican maria includ idl facil cost asset write-down facility-
relat cost incur
gross margin compar
non-gaap gross margin expens increas
compar
revenu flat compar
sg expens increas compar
sg revenu decreas
compar non-gaap sg expens revenu
compar
amort intang asset compar
restructur charg increas
compar
oper expens compar
oper profit decreas compar
non-gaap oper profit
non-gaap oper margin
interest expens compar
decreas interest expens due decreas total debt oblig
tax rate compar
increas due impact certain tax adjust gain
divestitur patient deep vein thrombosi nutrit
insuffici busi oper tax adjust along y/i
chang oper result jurisdict
non-gaap tax rate compar
chang non-gaap nomin tax rate due final certain tax
return audit impact laps feder statut limit
excess tax benefit relat stock-bas compens y/i chang
oper result jurisdict
net incom decreas compar
non-gaap net incom
gaap ep decreas compar
non-gaap ep
gaap ep decreas
compar
non-gaap ep
compar
net revenu increas compar
cog decreas compar
cog revenu
compar
decreas cog net sale favor affect infus
set recal diabet group along cost recogn relat
restor oper four puerto rico manufactur site
hurrican maria includ idl facil cost asset write-down
facility-rel cost incur
 expens increas compar
sg expens increas
compar
amort intang asset decreas compar
oper profit declin
compar
net incom declin compar
ep declin compar
oper four segment cardiac vascular group cvg
diabet group cvg segment contribut revenu mitg segment
contribut revenu rtg segment contribut revenu
diabet segment contribut revenu
net incom declin
compar
ep declin
compar
cardiac vascular group cvg cardiac vascular group segment
includ cardiac rhythm heart failur crhf coronari structur heart
csh aortic peripher vascular apv crhf contribut
segment revenu apv contribut segment revenu csh
contribut segment revenu
cardiac vascular group cvg
cardiac vascular
increas
compar
cardiac vascular group segment revenu increas
compar total revenu
increas compar
cvg revenu perform led high-singl digit growth csh apv
low-singl digit growth crhf constant currenc basi
cvg revenu
increas
compar
cvg revenu increas
compar cvg revenu non-u
develop market flat compar
cvg revenu emerg market increas
compar
develop manufactur market product diagnosi treatment
manag heart rhythm disord heart failur product includ
implant devic lead deliveri system product treatment
atrial fibril af product design reduc surgic site infect
inform system manag patient crhf devic
cardiac vascular group cvg
crhf revenu decreas compar
crhf revenu increas compar
arrhythmia manag grew mid-singl digit constant currenc
basi due high-singl digit constant currenc growth pace strong
sale micra transcathet pace azur wireless
pacemak arrhythmia manag result also led high-twenti
growth tyrx absorb antibacteri envelop mid-teen growth
constant currenc basi
therapi treat coronari arteri diseas cad heart valv disord
product includ coronari stent relat deliveri system includ line
accessori well product repair replac heart
valv perfus system posit stabil system beat heart
revascular surgeri surgic ablat product
csh revenu increas compar
total revenu increas
compar
growth led mid-teen constant currenc growth transcathet
aortic valv result global strength corevalv evolut
coronari grew mid-singl digit constant currenc basi led mid-
singl digit growth drug-elut stent low-doubl digit growth coronari
balloon high-teen growth guid cathet constant currenc
compar
csh revenu increas
compar
cardiac vascular group cvg
line product therapi treat aortic diseas aneurysm
dissect transect well peripher vascular diseas pvd
compar
balloon stent angioplasti system carotid embol protect system
treatment vascular diseas outsid heart product line includ
rang endovascular stent graft accessori includ endur
abdomin aortic aneurysm aaa stent graft system valiant captivia
compar
apv revenu increas compar
total revenu increas
compar
strength divis broad base high-teen growth
endoven given strong demand venas closur system low-
doubl digit growth pact admir drug-coat balloon dcb
continu strength japan mid-singl digit growth abdomin
group segment includ surgic innov si respiratori
gastrointestin renal divis si divis contribut
revenu divis contribut revenu
mitg revenu increas compar
total revenu decreas
compar
mitg revenu perform balanc high-singl digit constant
currenc growth si mitg revenu increas
compar
mitg revenu
increas
compar
mitg revenu non-u develop market declin
compar mitg revenu
emerg market increas compar
increas
compar
surgic innov si si divis develop manufactur market
product therapi treat diseas condit address
surgeon surgic innov busi includ sale stapl vessel seal
fixat hernia mechan devic mesh hardwar surgic instrument
sutur electro surgeri product
si divis revenu increas compar
total revenu increas
compar
growth led low-doubl digit constant currenc growth
advanc result strength ligasur vessel seal
instrument innov nano-co valleylab energi
platform advanc stapl grew high-singl digit constant
currenc basi led strong demand tri-stapl endo stapl
specialti reload signia power stapler
respiratori gastrointestin renal divis consist
respiratori monitor solut renal solut busi
respiratori monitor solut busi includ patient monitor
respiratori solut advanc ablat gi solut product line
renal solut busi includ renal access dialyz product
revenu increas compar
total revenu decreas
compar
growth led patient monitor grew high-singl
digit constant currenc basi result strength nellcor puls
oximetri gi solut grew low-doubl digit constant currenc
basi led strong perform gi diagnost renal solut
grew mid-singl digit constant currenc basi led strength
renal access product
restor therapi group rtg rtg includ spine brain therapi
specialti therapi pain therapi divis spine divis contribut
revenu brain therapi contribut revenu specialti
therapi contribut revenu pain therapi contribut
revenu
compar
growth led
grew high-
singl digit
result strength
rtg revenu increas compar
total revenu increas
compar
compar
group result led high-teen growth pain therapi low-
doubl digit growth specialti therapi high-singl digit growth brain
therapi flat result spine constant currenc basi
spine revenu flat
compar
total revenu flat
compar
rtg segment revenu increas
compar rtg revenu non-u
develop market increas compar
total revenu emerg market increas
compar
spine spine divis develop manufactur market line medic
devic implant use treatment spine musculoskelet
system product therapi treat rang condit affect spine
includ degen disc diseas spinal deform spinal tumor fractur
spine stenosi spine divis also provid biolog solut
orthoped dental market concert surgic technolog
busi offer navig neuromonitor power technolog design
spine procedur
spine revenu flat compar
total revenu flat compar
global spine revenu grew low-singl digit constant currenc
basi spine increas mid-singl digit constant
currenc basi posterior cervic grew low-doubl digit constant
currenc basi led recent launch infin oct
brain therapi brain therapi divis develop manufactur
market product therapi treat diseas vasculatur
around brain
product includ coil neurovascular stent flow divers product
well access deliveri product support procedur product offer
includ pipelin pipelin flex embol devic endovascular
treatment larg giant wide-neck brain aneurysm solitair fr
revascular devic treatment acut ischem stroke apollo
brain therapi revenu increas compar
total revenu increas
compar
neurovascular grew mid-teen constant currenc basi high-
twenti constant currenc growth stent acut ischem stroke
includ solitair platinum neurovascular also strength neuro
access product coil intrasaccular therapi flow divers product
neurosurgeri grew high-singl digit led strong capit equip
sale stealthstat surgic navig system mazor robot
guidanc system visualas mri-guid laser ablat system
specialti therapi specialti divis develop manufactur market
product therapi treat diseas condit ear nose
throat ent certain neurolog disord addit divis develop
manufactur market image-guid surgeri intra-op imag
system facilit surgic plan precis cranial spinal sinu
specialti therapi divis revenu increas
compar total revenu increas
compar result
led mid-teen constant currenc growth pelvic strong
sale interstim ii system
increas
compar
increas
compar
neurostimul target drug deliveri system manag
chronic pain common movement disord spastic urolog
gastrointestin disord portfolio neurostimul system
includ recharg non-recharg devic select lead
use treat chronic back and/or limb pain
portfolio product includ pain neurostimul system surescan
includ restoresensor recharg surescan mri
adaptivestim technolog devic use treat chronic intract
pain sever spastic associ cerebr palsi multipl sclerosi
spinal cord traumat brain injuri stroke
pain therapi divis revenu increas
compar total revenu increas
compar
divis strong mid-thirti constant currenc growth pain
stimul continu strength intelli platform spinal cord
stimul well low-doubl digit constant currenc growth target
diabet group diabet group divis develop manufactur
market integr diabet manag solut includ insulin pump
therapi continu glucos monitor cgm system therapi
manag softwar diabet group organ advanc
insulin manag aim emerg technolog divis
diabet group revenu increas
compar total revenu increas
compar group
experienc strong sustain global demand sensor-aug
revenu increas
compar
revenu increas
compar
diabet group revenu increas
compar diabet group revenu
non-u develop market increas
compar diabet group revenu
emerg market increas
compar
aim revenu grew mid-twenti constant currenc basi led
sustain market demand minim hybrid close loop
insulin pump system guardian sensor
aim launch minim sever european countri
quarter initi user feedback posit global adopt
sensor-aug insulin pump system result strong sensor
attach rate integr cgm sale grow mid-sixti
emerg technolog revenu doubl constant currenc
basi led on-going launch guardian connect cgm system
revenu
increas
compar
aim revenu grew
mid-twenti
led sustain
market demand
system
estim
organ
sale growth estim organ recent
exchang rate hold remaind mdt revenu would
neg affect
tax rate expect
free
cash flow expect
adjust ep expect growth
tax rate expect free cash flow expect
outstand
perform
quarter due strong
growth market
busi
cvg recent
graft system expect
captur share
growth especi
us western europ
outstand perform quarter due strong
growth market across multipl busi geographi
new product flow continu robust seri recent launch
led share gain new market develop also
pleas sustain execut emerg market grew
quarter
growth quarter led diabet grew reflect
strong demand minim hybrid close loop system
 outsid
minim invas therapi group grew quarter led
balanc growth across si divis sale advanc
product grew low-doubl digit led adopt enhanc
ligasur vessel seal instrument energi platform
advanc stapl grew high-singl digit innov
signia surgic stapl system tri-stapl endo stapl reload
continu perform well minim invas surgeri market
restor therapi group deliv strong perform growth
revenu due strong growth pain brain specialti therapi
divis rtg launch mazor stealth integr
robot navig platform acceler spine enabl
brain therapi react cathet riptid aspir system
along next-gener solitair revascular devic
contribut growth back half year
cvg recent approv valiant navion thorac stent graft system
expect captur share drive increment growth especi
us western europ japan look forward continu roll
recent launch crt-p azur line pacemak
pact admir drug-coat balloon introduct
heartwar hvad system
make continu progress pipelin opportun
growth futur
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
gross margin increas ttm basi compar due decreas cog
oper margin increas ttm basi compar
net margin declin ttm basi compar due increas tax rate
ep growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth plc januari
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale medtron plc januari
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset medtron plc januari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item medtron plc januari
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free plc januari
current price-to-earnings averag price-to-earnings due decreas stock price price-to-earnings
show huge fluctuat last three year due volatil stock price price-to-earnings trail
expect forward price-to-earnings
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc wellington manag compani massachusett servic price row associ lazard asset manag artisan partner limit jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard/windsor spdr etf vanguard specialized-health mf seri trust i-mf valu vanguard institut fund-institut vanguard/wellington fund dodg cox stock vanguard specialized-dividend appreci plc januari
developmentsfda approv smart programm interstim systemdecemb plc announc food drug administr fda approv interstim tm smart programm use interstim system provid sacral neuromodul therapi treatment overact bladder oab chronic fecal incontin fi non-obstruct urinari retent new smart programm streamlin multipl devic singl intuit touch screen samsung mobil devic enabl clinician person patient care allow patient manag therapi simpli discreetli oab fi treatabl extrem common embarrass condit adult unit state almost one six suffer oab nearli american one bowel incontin acquir nutrino healthnovemb plc nutrino health ltd lead provid nutrition-rel data servic analyt technolog announc compani enter definit agreement acquir nutrino given food nutrit central compon effect diabet manag compani recogn opportun improv clinic outcom peopl diabet integr nutrino extens food analysi infrastructur nutrit scienc expertis artifici intellig ai -driven person insight technolog futur innov receiv ce mark approv valiant navion tm thorac stent graft systemnovemb plc announc receiv ce mark approv valiant navion tm thorac stent graft system minim invas repair lesion descend thorac aorta includ thorac aortic aneurysm taa blunt traumat aortic injuri penetr atherosclerot ulcer pau intramur hematoma imh type aortic dissect tbad news also follow recent fda approvalof valiant navion system fda approv new synchrom tm ii myptm tm therapi manag enabl patient allevi unpredict painoctob plc announc food drug administr fda approv new synchrom tm ii myptm tm therapi manag patient chronic pain devic enabl patient allevi unpredict pain deliv on-demand bolus drug dose within therapeut limit set physician plc januari
incom statement
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit plc januari
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonmdtindustri avg avgprice/earn yield plc januari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
averag revenu estim
current qtr
next qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate medtron plc januari
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price volatil quarter declin decemb dip
stock declin period averag volum share
trade
stock price show upward trend year dip decemb
stock gave rel flat return past rang stock
stock show huge fluctuat quarter surg septemb
stock gave return past dip decemb
deliv strong perform quarter growth revenu due strong growth
across segment region non-gaap ep grew quarter
recommend buy rate stock tp base perform new
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
